id:"swepub:oai:lup.lub.lu.se:f23221e3-3a22-4750-b824-6b2c5bed82a6"
Search: id:"swepub:oai:lup.lub.lu.se:f23221e3-3a22-4750-b824-6b2c5bed82a6" > Long-term prophylax...
- 1 of 1
- Previous record
- Next record
- To hitlist
- Berntorp, ErikLund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups (author)
Long-term prophylaxis in von Willebrand disease
- Article/chapterEnglish2005
Publisher, publication year, extent ...
- 2005
Numbers
- LIBRIS-ID:oai:lup.lub.lu.se:f23221e3-3a22-4750-b824-6b2c5bed82a6
- https://lup.lub.lu.se/record/235902URI
Supplementary language notes
- Language:English
- Summary in:English
Part of subdatabase
- SwePubSwePub
Classification
Notes
- The majority of patients with von Willebrand disease (VWD) have a mild bleeding tendency that primarily involves mucosal bleeding. Some patients with the disorder, however, have severe episodes of mucosal or joint bleeding that can hamper daily activities and lead to significant joint impairment. Experience in the setting of severe hemophilia has shown the feasibility and benefits of prophylactic treatment to prevent bleeding and development of arthropathy. This approach also needs to be evaluated in patients with VWD who require repetitive treatment for bleeding episodes. Data from a series of 35 patients (with VWD types 3, 2A, 2B, and 1) who have received long-term prophylaxis at Malmo University Hospital and Karolinska University Hospital in Stockholm, Sweden, have demonstrated a substantial reduction of bleeding episodes since initiation of treatment. Patients who began prophylaxis at a young age (younger than 5 years) to prevent nose and mouth bleeds have had no joint bleeds and have no clinical signs of arthropathy. Treatment has been safe, with no cases of thrombosis, and no viral transmission among patients who received virus-aftenuated von Willebrand factor-containing factor VIII concentrate. These data thus suggest that long-term prophylaxis is warranted in the majority of patients with type 3 VWD and in other subtypes with severe bleeding tendencies, and that such an approach may help in the avoidance of joint disease if started early. More clinical data and controlled trials are needed in order to formulate recommendations for prophylaxis in patients with VWD.
Subject headings and genre
- MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
- MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
- von Willebrand disease
- bleeding disorders
- factor VIII
- von Willebrand
- factor
Added entries (persons, corporate bodies, meetings, titles ...)
- Petrini, P (author)
- Klinisk koagulationsmedicin, MalmöForskargrupper vid Lunds universitet (creator_code:org_t)
Related titles
- In:Blood Coagulation and Fibrinolysis16:Suppl 1, s. 23-261473-5733
Internet link
Find in a library
- Blood Coagulation and Fibrinolysis (Search for host publication in LIBRIS)
To the university's database
- 1 of 1
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Berntorp, Erik
- Petrini, P
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
- MEDICAL AND HEAL ...
- and Clinical Medicin ...
- and Hematology
- Articles in the publication
- Blood Coagulatio ...
- By the university
- Lund University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
